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We thank Drs Uzun, Sinha, and Beattie for taking interest in our
study. We fully agree that sustained fetal supraventricular tachycardia
and atrial flutter (AF) is a life-threatening situation, and maternal drug
therapy is therefore offered in the majority of these cases.
In 1980, the first report appeared of a hydropic fetus with
incessant supraventricular tachycardia that was successfully treated
with transplacental digoxin therapy.1 Since then numerous retrospec-
tive studies in fetal supraventricular arrhythmia (SVA) have looked
at different maternal drug therapies showing variable results.2
Our study indicates that digoxin and flecainide controls fetal SVA
more effectively than sotalol, although we were unable to find
differences in survival among the 3 drug cohorts. Despite relatively
low conversion rates, the overall arrhythmia-related mortality was
only 5%.3
The authors recommend the combination of digoxin and flecainide
as first-line therapy for fetal supraventricular tachycardia and AF,
even in the absence of hydrops. They base this on their excellent
results in 29 SVA cases that were treated in this way with fast
conversion rates and only 1 treatment failure.4 Their positive
findings are in line with the favorable results of digoxin and
flecainide as single or combination therapies as reported in our study.
The authors also point at the risks of using digoxin and flecainide
as single agents for fetal SVA. They use the well-known argument
that digoxin can facilitate rapid antegrade conduction over the
accessory pathway during atrial fibrillation or AF. We disagree with
this interpretation, because digoxin has been used safely in many
fetuses for many decades, and the risk of atrial fibrillation in
Wolf-Parkinson-White syndrome is extremely rare in the fetus or
newborn.2 Furthermore, at birth, ventricular preexcitation is present
in only a minority of fetal supraventricular tachycardia cases, and it
is an infrequent finding in fetal AF.5
Regarding the use of flecainide as monotherapy for fetal AF, we
agree on the potential risk of rapid 1:1 atrioventricular conduction
due to slowing of the AF rate, which may be prevented by adding
digoxin. Although it is rare, 1:1 atrioventricular conduction can
occur in fetal AF, as was shown in 2 of our cases before treatment.
Thus far, this complication has never been reported during maternal
flecainide treatment, which may be explained by the usually high
atrial rates in fetal AF.
We share the opinion of Dr Uzun and colleagues that flecainide
and digoxin in combination may offer theoretical advantages regard-
ing rhythm control and improvement of hemodynamics in the
hydropic fetus.2 Having said this, there is no evidence from random-
ized trials to support the superiority of this 2-drug combination over
single agents or other combinations such as digoxin and sotalol. This
emphasizes the need for a randomized trial, including arms with
combination treatment in hydropic fetuses. The feasibility of such a
trial is currently being investigated, and hopefully we can move
forward involving as many fetal medicine centers as possible to test
the different therapies in terms of efficacy and safety to develop
evidence-based guidelines for the optimal management of fetal SVA.
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